Dr. Philip D. Greenberg is the head of Immunology at the Fred Hutchinson Cancer Research Center, and a professor of medicine and immunology at the University of Washington.
Dr. Greenberg is known for his pioneering work in adoptive T cell immunotherapy, which he took from its experimental foundations in the laboratory and brought into the clinic as a treatment for blood cancers. For these contributions, he was awarded the 2011 William B. Coley Award. Now, Dr. Greenberg is focused on expanding the use of adoptive T cell immunotherapies to other cancers, so that more patients can benefit.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. Greenberg serves on the Postdoctoral Fellowship Review Committee and is a member of CRI’s Clinical Leadership Committee. He is also the editor-in-chief of the CRI-AACR journal Cancer Immunology Research.
Now, we can change T cells to make them function better, make them survive better, make them target the cancer better. The things we’re doing now, we couldn’t even have dreamed about back when I started.
Let's spread the word about Immunotherapy! Click to share this page with your community.